Sellas Life Sciences reported that its experimental blood cancer immunotherapy, galinpepimut-S, reduced the risk of death by 41% versus standard treatment in a Phase 3 trial in advanced acute myeloid leukemia, achieving the main goal, according to STAT+. The company is presenting the outcome as a survival benefit aligned with the trial’s primary endpoint. The result suggests potential for the therapy to become part of future AML treatment strategies, particularly if confirmatory details—such as subgroup performance and durability—remain favorable as further data mature. For clinicians and product developers, the readout strengthens the case for continued investment in immunotherapy approaches in AML beyond chemotherapy-only frameworks.
Get the Daily Brief